Logo
x

Search

Subscribe Now

Postmenopausal Women

Astellas Reports Results of Fezolinetant in Two P-III Studies for the Nonhormonal Treatment of VMS in Postmenopausal Women

Astellas Reports Results of Fezolinetant in Two P-III Studies for the Nonhormonal Treatment of VMS in Postmenopausal Women

  • February 22, 2021
Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of F...

  • December 12, 2019
Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High R...

  • October 18, 2019
Amgen Canada's EVENITY (romosozumab) Receives Health Canada Approval to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture

Amgen Canada's EVENITY (romosozumab) Receives Health Canada Approval to Treat Osteoporosis in Postmenopausal Women at High Risk fo...

  • October 9, 2019
Amgen's Evenity (romosozumab-aqqg) Receives FDA's Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture

Amgen's Evenity (romosozumab-aqqg) Receives FDA's Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture

  • April 10, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.